Last updated on November 2019

Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors


Brief description of study

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

Detailed Study Description

The study consists of 2 parts, a dose-escalation part (Phase 1) and an expansion part (Phase 2). Both parts will enroll patients with advanced non-resectable NSCLC, advanced non-resectable thyroid cancer and other advanced solid tumors that have progressed following standard systemic therapy, have not adequately responded to standard systemic therapy, or the patients must be intolerant to or the Investigator has determined that treatment with standard therapy is not appropriate, or there must be no accepted standard therapy for their disease.

Clinical Study Identifier: NCT03037385

Find a site near you

Start Over

Mayo Clinic

Phoenix, AZ United States
  Connect »

UC Irvine Medical Center

Orange, CA United States
  Connect »

Mayo Clinic

Jacksonville, FL United States
  Connect »

University of Michigan

Ann Arbor, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Cornell University

New York, NY United States
  Connect »

Gustave Roussy

Villejuif, France
  Connect »

Severance Hospital

Seoul, Korea, Republic of
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »